J Korean Ophthalmol Soc > Volume 49(8); 2008 > Article
Journal of the Korean Ophthalmological Society 2008;49(8):1275-1282.
DOI: https://doi.org/10.3341/jkos.2008.49.8.1275    Published online August 15, 2008.
Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema.
Jong Youn Kim, Eui Yong Kweon, Dong Wook Lee, Nam Chun Cho
Department of Ophthalmology, Chonbuk National University, School of Medicine, Jeonju, Korea. key@chonbuk.ac.kr
망막정맥폐쇄 및 당뇨병에 의한 황반부종 환자에서 유리체강내 베바시주맙 주입술의 단기효과
김종연ㆍ권의용ㆍ이동욱ㆍ조남천
Department of Ophthalmology, Chonbuk National University, School of Medicine, Jeonju, Korea
Abstract
PURPOSE
To evaluate the short-term effect and safety of intravitreally injected bevacizumab in patients with macular edema (ME) caused by retinal vein occlusion (RVO) and diabetic macular edema (DME). METHODS: We retrospectively evaluated 59 eyes of 51 patients, 29 with ME caused by RVO and 30 with DME, who received intravitreal injection of bevacizumab. Fifty-one consecutive patients (59 eyes) with ME associated with RVO and DME were treated with intravitreal injections of 1.25-2.5 mg (0.05-0.1 ml) of bevacizumab. Ophthalmic evaluation was performed at baseline and at 1, 3, 6 months after each injection. Clinical evidence of toxicity and complications, changes of visual acuity with an ETDRS chart (LogMAR), and central macular thickness (CMT) using optical coherence tomography (OCT), were evaluated. RESULTS: The follow-up period was 7.3 months (7.3+/-0.31) and the mean number of injections was 1.2. The baseline mean LogMAR was 1.06+/-0.53 and mean CMT was 479.6+/-160.4 micrometer. At 1, 3 and 6 months, the mean LogMAR was 0.90+/-0.52, 0.80+/-0.39 and 0.78+/-0.39, respectively, and the mean CMT was 316.9+/-86.7 micrometer, 281.1+/-67.4 micrometer and 278.4+/-64.6 micrometer, respectively. No adverse incidents were observed, including cataract, retinal detachment, vitreous hemorrhage, and endophthalmitis, although transient increased intraocular pressure was observed. CONCLUSIONS: Intravitreal bevacizumab injections are safe and effective in ME caused by RVO and DME.
Key Words: Bevacizumab (Avastin(R));Macular edema;Vascular endothelial growth factor (VEGF)


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next